TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery
Brief Summary: Worldwide over 2 million adults (\>30,000 Canadians) undergo heart surgery annually. Although heart surgery provides important survival benefits, it is associated with potential major complications such as death, stroke, and heart attack. There is promising evidence that measurement of heart injury markers after surgery will identify patients at risk of death or major complications.

This study will determine the current incidence of major complications in a representative sample of 15,000 contemporary adult patients undergoing heart surgery. Knowing the current burden of complications will inform clinicians, administrators, government and granting agencies about resources required to address the problem. This study will also establish the role of measuring heart injury markers to identify important heart injury after heart surgery and the proportion that would go undetected without routine heart injury marker monitoring. This information will facilitate further studies of timely interventions. In summary, the VISION Cardiac Surgery Study addresses fundamental questions that will have profound public health implications given the millions of adults worldwide who undergo heart surgery annually.


Options:
A: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
C: Arm Label: Coronary Stent; Type: N/A; Interventions: N/A
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials
Brief Summary: This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.


Options:
A: Arm Label: Mepolizumab Arm; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab Arm
B: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials
Brief Summary: This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.


Options:
A: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)
B: Arm Label: Mepolizumab Arm; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab Arm
C: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Xolair; Type: EXPERIMENTAL; Interventions: Drug: omalizumab (Xolair), Drug: corticosteroids, Drug: long-acting beta-agonists | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: corticosteroids, Drug: long-acting beta-agonists | Intervention Type: DRUG; Name: omalizumab (Xolair); Assigned to Arm(s): Xolair | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: corticosteroids; Assigned to Arm(s): Xolair, placebo | Intervention Type: DRUG; Name: long-acting beta-agonists; Assigned to Arm(s): Xolair, placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Second RCT Evaluation of the Durham Connects Universal Newborn Nurse Home Visiting Program
Brief Summary: The aim of this randomized controlled trial (RCT) is to conduct a second, independent evaluation the implementation and impact of the Durham Connects (DC) brief universal nurse home-visiting program to prevent child maltreatment and improve child and family health and well-being. Durham Connects is the first home-visiting program that is designed to prevent child maltreatment and improve health and well-being outcomes in an entire community population.

Program evaluation will test four hypotheses: 1) The program can be implemented with population reach, fidelity to the manualized intervention protocol, and reliability in assessment of family risk; 2) Random assignment to the Durham Connects program will be associated with lower rates of child maltreatment and emergency department maltreatment-related injuries, better pediatric care, better parental functioning, and better child well-being than assignment as control; 2) Intervention effect sizes will be larger for higher-risk groups; and 3) Community resource use and enhanced family functioning will mediate the positive impact of Durham Connects on outcomes.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Relaxation; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation | Intervention Type: BEHAVIORAL; Name: Relaxation; Assigned to Arm(s): Relaxation
C: Arm Label: Durham Connects Eligible; Type: EXPERIMENTAL; Interventions: Other: Durham Connects | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Durham Connects; Assigned to Arm(s): Durham Connects Eligible
D: Arm Label: Mother Touch Program; Type: EXPERIMENTAL; Interventions: Other: Mothers Touch Program | Arm Label: Usual care Program; Type: OTHER; Interventions: Other: Usual Care Program | Intervention Type: OTHER; Name: Mothers Touch Program; Assigned to Arm(s): Mother Touch Program | Intervention Type: OTHER; Name: Usual Care Program; Assigned to Arm(s): Usual care Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Vaginal Estrogen With Pessary Treatment of Pelvic Organ Prolapse and Urinary Incontinence
Brief Summary: Patients presenting with pelvic organ prolapse will be offered the use of a pessary. Vaginal estrogen cream treatment with the pessary will be randomized amongst the patients and patient satisfaction and complication rates will be assessed during follow-up.


Options:
A: Arm Label: Treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Premarin vaginal cream | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo cream | Intervention Type: DRUG; Name: Premarin vaginal cream; Assigned to Arm(s): Treatment group | Intervention Type: DRUG; Name: Placebo cream; Assigned to Arm(s): Control group
B: Arm Label: Intravaginal Pessary; Type: EXPERIMENTAL; Interventions: Device: Intravaginal Pessary | Arm Label: Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Therapy | Arm Label: Pessary combined with behavioral therapy; Type: EXPERIMENTAL; Interventions: Device: Pessary combined with behavioral therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Therapy; Assigned to Arm(s): Behavioral Therapy | Intervention Type: DEVICE; Name: Intravaginal Pessary; Assigned to Arm(s): Intravaginal Pessary | Intervention Type: DEVICE; Name: Pessary combined with behavioral therapy; Assigned to Arm(s): Pessary combined with behavioral therapy
C: Arm Label: Linoladiol Estradiol; Type: EXPERIMENTAL; Interventions: Drug: Linoladiol Estradiol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo vaginal cream | Intervention Type: DRUG; Name: Linoladiol Estradiol; Assigned to Arm(s): Linoladiol Estradiol | Intervention Type: OTHER; Name: Placebo vaginal cream; Assigned to Arm(s): Placebo
D: Arm Label: Estrogen Cream; Type: EXPERIMENTAL; Interventions: Drug: Conjugated Estrogens Cream | Arm Label: Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Cream | Intervention Type: DRUG; Name: Conjugated Estrogens Cream; Assigned to Arm(s): Estrogen Cream | Intervention Type: DRUG; Name: Placebo Cream; Assigned to Arm(s): Placebo Cream

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Multicenter Feasibility Study of an IncisionLEss Operating Platform for Primary ObeSiTy vs. Diet-exercise Alone: The MILEPOST Study
Brief Summary: This study is a multi-center, open/unblended study (3:1Treatment: Control) to evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight loss intervention compared to a diet and exercise control only. Mean % Total Body Weight Loss \[TBWL\] in Treatment subjects versus that of Control subjects at 12 months is the primary endpoint. The proportion of subjects achieving ≥ 5% TBWL at 12 months in the treatment group is a co-primary endpoint.


Options:
A: Arm Label: Laparoscopic adjustable gastric band; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic adjustable gastric band, Behavioral: Combined life style interventions | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Combined life style interventions | Intervention Type: PROCEDURE; Name: laparoscopic adjustable gastric band; Assigned to Arm(s): Laparoscopic adjustable gastric band | Intervention Type: BEHAVIORAL; Name: Combined life style interventions; Assigned to Arm(s): Control group, Laparoscopic adjustable gastric band
B: Arm Label: g-Cath EZ Treatment Group; Type: EXPERIMENTAL; Interventions: Device: g-CathTM EZ Suture Anchor Delivery Catheter | Arm Label: Diet and exercise Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet and Exercise Control Group | Intervention Type: DEVICE; Name: g-CathTM EZ Suture Anchor Delivery Catheter; Assigned to Arm(s): g-Cath EZ Treatment Group | Intervention Type: OTHER; Name: Diet and Exercise Control Group; Assigned to Arm(s): Diet and exercise Control Group
C: Arm Label: Stapleless one anastomosis gastric bypass; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic one anastomosis gastric bypass | Arm Label: Staple use mini-gastric bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic one anastomosis gastric bypass | Arm Label: Hypocaloric diet therapy; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Hypocaloric diet therapy | Intervention Type: PROCEDURE; Name: Laparoscopic one anastomosis gastric bypass; Assigned to Arm(s): Staple use mini-gastric bypass, Stapleless one anastomosis gastric bypass | Intervention Type: DIETARY_SUPPLEMENT; Name: Hypocaloric diet therapy; Assigned to Arm(s): Hypocaloric diet therapy
D: Arm Label: Adolescents with severe obesity; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Roxithromycin is effective in the treatment of intracellular organisms, including chlamydia and mycoplasma, and exhibits anti-inflammatory and immunomodulatory effects on respiratory diseases. To explore the potential therapeutic benefit of roxithromycin in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), this study compared the effect of roxithromycin with ciprofloxacin and aceclofenac.


Options:
A: Arm Label: Silodosin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 4 mg | Arm Label: Silodosin 8 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 8 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Silodosin 8 mg; Assigned to Arm(s): Silodosin 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Silodosin 4 mg; Assigned to Arm(s): Silodosin 4 mg
B: N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Alfuzosin; Type: EXPERIMENTAL; Interventions: Drug: Alfuzosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alfuzosin; Assigned to Arm(s): Alfuzosin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Promotion Coaching/Vaccine for Homeless Parolees
Brief Summary: The purpose of this study is to conduct a prospective, three-group study that randomly assigns 700 parolees, in a community residential drug treatment program, to enter one of three groups: 1) a PCPC (Parolee Comprehensive Care + Phone Coaching Program), which includes nurse case management and specialized hepatitis education sessions and the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone); 2) a Parolee Brief Hepatitis Education + HBV vaccination + Phone Coaching (PBCP) Program, which includes brief hepatitis/HIV education, HAV/HBV vaccination and coach-facilitated mentoring; or 3) a Usual Care (UC) control program, which includes brief general health information, one-on-one coaching and the HAV/HBV vaccine.


Options:
A: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
B: Arm Label: Parolee Comprehensive Care + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach | Arm Label: Parolee Brief HBV program + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Brief HBV Program + Phone Coach | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Intervention Type: BEHAVIORAL; Name: Parolee Comprehensive Care + Phone Coach; Assigned to Arm(s): Parolee Comprehensive Care + Phone Coach | Intervention Type: BEHAVIORAL; Name: Parolee Brief HBV Program + Phone Coach; Assigned to Arm(s): Parolee Brief HBV program + Phone Coach | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group
C: Arm Label: TAU only; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Outpatient Treatment | Arm Label: TMAC only; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling | Arm Label: TMAC plus; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling plus incentives | Intervention Type: OTHER; Name: Intensive Outpatient Treatment; Assigned to Arm(s): TAU only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling; Assigned to Arm(s): TMAC only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling plus incentives; Assigned to Arm(s): TMAC plus
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Screening for intimate partner violence | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening for intimate partner violence; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Promotion Coaching/Vaccine for Homeless Parolees
Brief Summary: The purpose of this study is to conduct a prospective, three-group study that randomly assigns 700 parolees, in a community residential drug treatment program, to enter one of three groups: 1) a PCPC (Parolee Comprehensive Care + Phone Coaching Program), which includes nurse case management and specialized hepatitis education sessions and the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone); 2) a Parolee Brief Hepatitis Education + HBV vaccination + Phone Coaching (PBCP) Program, which includes brief hepatitis/HIV education, HAV/HBV vaccination and coach-facilitated mentoring; or 3) a Usual Care (UC) control program, which includes brief general health information, one-on-one coaching and the HAV/HBV vaccine.


Options:
A: Arm Label: Parolee Comprehensive Care + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach | Arm Label: Parolee Brief HBV program + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Brief HBV Program + Phone Coach | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Intervention Type: BEHAVIORAL; Name: Parolee Comprehensive Care + Phone Coach; Assigned to Arm(s): Parolee Comprehensive Care + Phone Coach | Intervention Type: BEHAVIORAL; Name: Parolee Brief HBV Program + Phone Coach; Assigned to Arm(s): Parolee Brief HBV program + Phone Coach | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group
B: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: PR OROS Methylphenidate | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PR OROS Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill
C: Arm Label: tenofovir disoproxil fumarate; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir disoproxil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tenofovir disoproxil; Assigned to Arm(s): tenofovir disoproxil fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Re-entry Modified Therapeutic Community (Re-entry MTC); Type: EXPERIMENTAL; Interventions: Behavioral: Re-entry Modified Therapeutic Community (Re-entry MTC) | Arm Label: Parole Supervision and Case Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parole Supervision and Case Management | Intervention Type: BEHAVIORAL; Name: Re-entry Modified Therapeutic Community (Re-entry MTC); Assigned to Arm(s): Re-entry Modified Therapeutic Community (Re-entry MTC) | Intervention Type: BEHAVIORAL; Name: Parole Supervision and Case Management; Assigned to Arm(s): Parole Supervision and Case Management

Answer: A